Abstract
Patients with end-stage renal disease (ESRD) due to atypical HUS (aHUS) now have several potential options that can enable successful kidney transplantation. This editorial addresses these options by considering key factors that are important when making an individual treatment decision.
MeSH terms
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Atypical Hemolytic Uremic Syndrome
-
Complement Factor H / deficiency*
-
Complement Factor H / genetics
-
Female
-
Hemolytic-Uremic Syndrome / surgery*
-
Hereditary Complement Deficiency Diseases
-
Humans
-
Immunosuppressive Agents / therapeutic use*
-
Kidney Diseases / complications*
-
Kidney Transplantation*
-
Liver Transplantation*
-
Mutation*
-
Plasma Exchange*
Substances
-
Antibodies, Monoclonal, Humanized
-
CFH protein, human
-
Immunosuppressive Agents
-
Complement Factor H
-
eculizumab
Supplementary concepts
-
Complement Factor H Deficiency